B-intervention	0	10	Epirubicin
I-intervention	11	14	and
I-intervention	15	24	docetaxel
I-intervention	25	29	with
I-intervention	30	32	or
I-intervention	33	40	without
I-intervention	41	53	capecitabine
O	54	56	as
O	57	68	neoadjuvant
O	69	78	treatment
O	79	82	for
O	83	88	early
O	89	95	breast
O	96	102	cancer
O	102	103	:
O	104	109	final
O	110	117	results
O	118	120	of
O	121	122	a
O	123	133	randomized
O	134	139	phase
O	140	143	III
O	144	149	study
O	150	151	(
O	151	156	ABCSG
O	156	157	-
O	157	159	24
O	159	160	)
O	160	161	.

O	162	166	This
O	167	177	randomized
O	178	183	phase
O	184	187	III
O	188	193	trial
O	194	202	compared
O	203	213	pathologic
O	214	222	complete
O	223	231	response
O	232	233	(
O	233	236	pCR
O	236	237	)
O	238	243	rates
O	244	246	of
O	247	252	early
O	253	259	breast
O	260	266	cancer
O	267	268	(
O	268	271	EBC
O	271	272	)
O	273	282	following
O	283	294	neoadjuvant
O	295	305	epirubicin
O	305	306	-
O	306	315	docetaxel
O	316	317	(
O	317	319	ED
O	319	320	)
O	320	321	±
O	321	333	capecitabine
O	334	335	(
O	335	336	C
O	336	337	)
O	337	338	,
O	339	342	and
O	343	352	evaluated
O	353	356	the
O	357	365	addition
O	366	368	of
O	369	380	trastuzumab
O	381	383	in
O	384	388	HER2
O	388	389	-
O	389	397	positive
O	398	404	tumors
O	404	405	.

B-eligibility	406	414	Patients
I-eligibility	415	419	with
I-eligibility	420	428	invasive
I-eligibility	429	435	breast
I-eligibility	436	442	cancer
I-eligibility	443	444	(
I-eligibility	444	450	except
I-eligibility	451	454	T4d
I-eligibility	454	455	)
O	456	460	were
O	461	469	randomly
O	470	478	assigned
O	479	481	to
O	482	489	receive
O	490	493	six
O	494	495	3
O	495	496	-
O	496	502	weekly
O	503	509	cycles
O	510	512	of
O	513	515	ED
O	516	517	(
O	517	521	both
O	522	524	75
O	525	527	mg
O	527	528	/
O	528	530	m2
O	530	531	)
O	531	532	±
O	532	533	C
O	534	535	(
O	535	539	1000
O	540	542	mg
O	542	543	/
O	543	545	m2
O	545	546	,
O	547	552	twice
O	553	558	daily
O	558	559	,
O	560	564	days
O	565	566	1
O	566	567	-
O	567	569	14
O	569	570	)
O	570	571	.

O	572	580	Patients
O	581	585	with
O	586	590	HER2
O	590	591	-
O	591	599	positive
O	600	607	disease
O	608	612	were
O	613	620	further
O	621	631	randomized
O	632	634	to
O	635	642	receive
O	643	654	trastuzumab
O	655	656	(
O	656	657	8
O	658	660	mg
O	660	661	/
O	661	663	kg
O	663	664	,
O	665	669	then
O	670	671	6
O	672	674	mg
O	674	675	/
O	675	677	kg
O	678	683	every
O	684	685	3
O	686	691	weeks
O	691	692	)
O	693	695	or
O	696	699	not
O	699	700	.

O	701	708	Primary
O	709	712	end
O	713	718	point
O	718	719	:
B-outcome-Measure	720	723	pCR
I-outcome-Measure	724	728	rate
I-outcome-Measure	729	731	at
I-outcome-Measure	732	735	the
I-outcome-Measure	736	740	time
I-outcome-Measure	741	743	of
I-outcome-Measure	744	751	surgery
O	751	752	.

B-total-participants	753	757	Five
I-total-participants	758	765	hundred
I-total-participants	766	772	thirty
I-total-participants	772	773	-
I-total-participants	773	776	six
O	777	785	patients
O	786	790	were
O	791	801	randomized
O	802	804	to
B-control	805	807	ED
O	808	809	(
O	809	810	n
O	810	811	=
B-control-participants	811	814	266
O	814	815	)
O	816	818	or
O	819	822	EDC
O	823	824	(
O	824	825	n
O	825	826	=
B-intervention-participants	826	829	270
O	829	830	)
O	830	831	;
O	832	834	93
O	835	843	patients
O	844	848	were
O	849	856	further
O	857	867	randomized
O	868	870	to
O	871	882	trastuzumab
O	883	884	(
O	884	885	n
O	885	886	=
B-intervention-participants	886	888	44
O	888	889	)
O	890	892	or
B-control	893	896	not
O	897	898	(
O	898	899	n
O	899	900	=
B-control-participants	900	902	49
O	902	903	)
O	903	904	.

B-outcome	905	908	pCR
I-outcome	909	913	rate
O	914	917	was
O	918	931	significantly
O	932	941	increased
O	942	946	with
O	947	950	EDC
O	951	952	(
B-iv-bin-percent	952	954	23
I-iv-bin-percent	954	955	.
I-iv-bin-percent	955	956	0
I-iv-bin-percent	956	957	%
O	958	964	versus
B-cv-bin-percent	965	967	15
I-cv-bin-percent	967	968	.
I-cv-bin-percent	968	969	4
I-cv-bin-percent	969	970	%
O	971	973	ED
O	973	974	,
O	975	976	P
O	976	977	=
O	977	978	0
O	978	979	.
O	979	982	027
O	982	983	)
O	983	984	,
O	985	988	and
O	989	1005	nonsignificantly
O	1006	1013	further
O	1014	1023	increased
O	1024	1028	with
O	1029	1040	trastuzumab
O	1041	1042	(
B-iv-bin-percent	1042	1044	38
I-iv-bin-percent	1044	1045	.
I-iv-bin-percent	1045	1046	6
I-iv-bin-percent	1046	1047	%
O	1048	1051	EDC
O	1052	1058	versus
B-cv-bin-percent	1059	1061	26
I-cv-bin-percent	1061	1062	.
I-cv-bin-percent	1062	1063	5
I-cv-bin-percent	1063	1064	%
O	1065	1067	ED
O	1067	1068	,
O	1069	1070	P
O	1070	1071	=
O	1071	1072	0
O	1072	1073	.
O	1073	1076	212
O	1076	1077	)
O	1077	1078	.

B-outcome	1079	1084	Rates
I-outcome	1085	1087	of
I-outcome	1088	1096	axillary
I-outcome	1097	1101	node
I-outcome	1102	1113	involvement
O	1114	1116	at
O	1117	1124	surgery
O	1125	1128	and
B-outcome	1129	1135	breast
I-outcome	1136	1148	conservation
O	1149	1153	were
O	1154	1162	improved
O	1163	1167	with
O	1168	1171	EDC
O	1172	1178	versus
O	1179	1181	ED
O	1181	1182	,
O	1183	1186	but
O	1187	1190	not
O	1191	1204	significantly
O	1204	1205	;
O	1206	1209	the
O	1210	1218	addition
O	1219	1221	of
O	1222	1233	trastuzumab
O	1234	1237	had
O	1238	1240	no
O	1241	1248	further
O	1249	1255	impact
O	1255	1256	.

O	1257	1264	Hormone
O	1265	1273	receptor
O	1274	1280	status
O	1280	1281	,
O	1282	1287	tumor
O	1288	1292	size
O	1292	1293	,
O	1294	1299	grade
O	1299	1300	,
O	1301	1304	and
O	1305	1306	C
O	1307	1308	(
O	1308	1311	all
O	1312	1313	P
O	1313	1314	≤
O	1314	1315	0
O	1315	1316	.
O	1316	1319	035
O	1319	1320	)
O	1321	1325	were
O	1326	1337	independent
O	1338	1348	prognostic
O	1349	1356	factors
O	1357	1360	for
O	1361	1364	pCR
O	1364	1365	.

O	1366	1377	Trastuzumab
O	1378	1383	added
O	1384	1386	to
O	1387	1389	ED
O	1389	1390	±
O	1390	1391	C
O	1392	1405	significantly
O	1406	1415	increased
O	1416	1419	the
B-outcome	1420	1426	number
I-outcome	1427	1429	of
I-outcome	1430	1437	serious
I-outcome	1438	1445	adverse
I-outcome	1446	1452	events
O	1453	1454	(
B-iv-bin-abs	1454	1456	35
O	1457	1463	versus
B-cv-bin-abs	1464	1466	18
O	1466	1467	;
O	1468	1469	P
O	1469	1470	=
O	1470	1471	0
O	1471	1472	.
O	1472	1475	020
O	1475	1476	)
O	1476	1477	,
O	1478	1484	mainly
O	1485	1488	due
O	1489	1491	to
O	1492	1500	infusion
O	1500	1501	-
O	1501	1508	related
O	1509	1518	reactions
O	1518	1519	.

O	1520	1525	These
O	1526	1534	findings
O	1535	1539	show
O	1540	1544	that
O	1545	1548	the
O	1549	1560	integration
O	1561	1563	of
O	1564	1565	C
O	1566	1570	into
O	1571	1572	a
O	1573	1584	neoadjuvant
O	1585	1591	taxane
O	1591	1592	-
O	1592	1593	/
O	1593	1606	anthracycline
O	1606	1607	-
O	1607	1612	based
O	1613	1620	regimen
O	1621	1623	is
O	1624	1625	a
O	1626	1634	feasible
O	1634	1635	,
O	1636	1640	safe
O	1640	1641	,
O	1642	1645	and
O	1646	1655	effective
O	1656	1665	treatment
O	1666	1672	option
O	1672	1673	,
O	1674	1678	with
O	1679	1692	incorporation
O	1693	1695	of
O	1696	1707	trastuzumab
O	1708	1710	in
O	1711	1715	HER2
O	1715	1716	-
O	1716	1724	positive
O	1725	1732	disease
O	1732	1733	.

O	1734	1745	NCT00309556
O	1745	1746	,
O	1747	1750	www
O	1750	1751	.
O	1751	1765	clinicaltrials
O	1765	1766	.
O	1766	1769	gov
O	1769	1770	.
